ViroLogic Announces Presentations on Its eTag Technology at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO)

ViroLogic Announces Presentations on Its eTag Technology at the
2005 American Society of Clinical Oncology Annual Meeting (ASCO) 


SOUTH SAN FRANCISCO, Calif., May 4  /PRNewswire-FirstCall/ -- ViroLogic, Inc.
(NASDAQ:VLGC) announced today multiple presentations and publications related
to its eTag(TM) technology. The presentations and publications are part of the
proceedings at the 2005 American Society of Clinical Oncology Annual Meeting
(ASCO) being held May 13-17, 2005 at the Orange County Convention Center in
Orlando, FL.

  ViroLogic scientists will make the following presentations:

   Sunday, May 15, 2005
   Session:  Tumor Biology and Human Genetics
   Title:  Analysis of ErbB/HER Receptor Pathways in Formalin-fixed and
   Paraffin-embedded Cancer Cell Lines using Multiplexed eTag Assays
   Abstract #9565:  8:00 a.m. - 12:00 p.m.

   Session:  Tumor Biology and Human Genetics
   Title:  Detection of Vascular Endothelial Growth Factor Receptor 2
   (VEGFR2) Homodimers, Phosphorylation and Downstream Pathway Activation in
   Endothelial Cells using eTag Assay System
   Abstract #9595:  8:00 a.m. - 12:00 p.m.

   Monday, May 16, 2005
   Session:  Breast Cancer
   Title:  ErbB/HER Pathway Profiling in Formalin-fixed Paraffin-embedded
   Tissues using Multiplexed Proximity-based Assays
   Abstract #645:  2:00 - 6:00 p.m.

   Session:  Breast Cancer
   Title:  ErbB/Her Dimerization in Breast and Lung Cancer
   Abstract #643:  2:00 - 6:00 p.m.

   Tuesday, May 17, 2005
   Session:  Breast Cancer II
   Title:  The use of ErbB/HER Activation Status as Prognostic Markers in
   Breast Cancer Patients Treated with Trastuzumab (Herceptin(R))
   Abstract #553:  8:00 a.m. - 12:00 p.m. Poster Discussion

   eTAG Published Abstracts
   Abstract #9618
   Title:  Predictive Value of eTag Dimerization Assay in Patients with
   Metastatic
   Colorectal Cancer Treated with Erlotinib (Tarceva(R))

   Abstract #808
   Title:  ErbB/Her Dimerization Profiles and Targeted Therapy in Breast and
   Lung Cancer

   Abstract #3172
   Title:  Effect of Gefitinib (Iressa(R)) on EGFR Mutated Lung Cancer Cell
   Lines

  About the eTag System


ViroLogic's eTag assays enable detailed analysis of protein drug targets and
signaling pathways in cancer cells, including samples that are formalin-fixed,
paraffin-embedded, which is the standard format in most pathology labs. The
assays can provide information on a drug's mechanism of action, selectivity and
potency in a biological setting in pre-clinical research, and enable enrichment
or selection of clinical trial populations later in a drug's development. In
addition, ViroLogic believes these assays will be used to help physicians
better determine whether certain therapies are more appropriate for individual
cancer patients, and whether to combine therapies with different mechanisms or
properties.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology is also
being used by numerous biopharmaceutical companies to develop new and improved
antiviral therapeutics and vaccines as well as targeted cancer therapeutics.
More information about the Company and its technology can be found on its web
site at http://www.virologic.com/.

NOTE:  eTag is a trademark of ViroLogic, Inc. Herceptin(R) and Tarceva(R) are
registered trademarks of Genentech. Iressa(R) is a registered trademark of
AstraZeneca. 

DATASOURCE: ViroLogic, Inc.



CONTACT:  Alfred Merriweather, Vice President and CFO of ViroLogic,

[phone]; or Carolyn Bumgardner Wang of WeissComm Partners,

[phone], or , for ViroLogic



Web site:  http://www.virologic.com/

Copyright